COPS5 and breast carcinoma: Of note, breast cancer cells with overexpression of COPS5 appeared to be less sensitive to the SERD fulvestrant in vitro as well (Supplementary Fig. 2), suggesting that it could be a common resistance mechanism to endocrine therapies.